WO2012081570A1 - Composé de lactame ou d'un sel de ce dernier, et activateur de ppar - Google Patents

Composé de lactame ou d'un sel de ce dernier, et activateur de ppar Download PDF

Info

Publication number
WO2012081570A1
WO2012081570A1 PCT/JP2011/078767 JP2011078767W WO2012081570A1 WO 2012081570 A1 WO2012081570 A1 WO 2012081570A1 JP 2011078767 W JP2011078767 W JP 2011078767W WO 2012081570 A1 WO2012081570 A1 WO 2012081570A1
Authority
WO
WIPO (PCT)
Prior art keywords
isoindoline
mmol
group
alkyl
ring
Prior art date
Application number
PCT/JP2011/078767
Other languages
English (en)
Japanese (ja)
Inventor
知士 青塚
一 金澤
健太郎 熊沢
Original Assignee
あすか製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by あすか製薬株式会社 filed Critical あすか製薬株式会社
Priority to JP2012548787A priority Critical patent/JPWO2012081570A1/ja
Publication of WO2012081570A1 publication Critical patent/WO2012081570A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Cette invention concerne un composé de lactame ou d'un sel de ce dernier représenté par la formule (1), lequel composé possède un squelette de lactame ou d'un sel de lactame et convient comme activateur de PPAR. [Dans cette formule, le noyau Z correspond à un noyau hydrocarboné condensé ou un noyau hétérocyclique ; R1 désigne des atomes d'halogène identiques ou différents, des groupes alkyle pouvant avoir un groupe substitué, des groupes hydroxyle, ou des groupes alkoxy pouvant avoir un groupe substitué ; R2 désigne un groupe alkylène pouvant avoir une liaison directe ou un groupe substitué ; R3 désigne un groupe alkoxy pouvant avoir un groupe hydroxyle ou un groupe substitué ; le lieur (X) compte 1-10 atomes dans la chaine principale pris dans des atomes de carbone et des hétéro atomes, et la chaîne principale peut avoir un groupe substitué ; Y désigne une liaison directe, un atome d'oxygène ou un atome de soufre ; et k est un entier compris entre 0 et 5.]
PCT/JP2011/078767 2010-12-14 2011-12-13 Composé de lactame ou d'un sel de ce dernier, et activateur de ppar WO2012081570A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012548787A JPWO2012081570A1 (ja) 2010-12-14 2011-12-13 ラクタム化合物又はその塩及びｐｐａｒ活性化剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010277978 2010-12-14
JP2010-277978 2010-12-14

Publications (1)

Publication Number Publication Date
WO2012081570A1 true WO2012081570A1 (fr) 2012-06-21

Family

ID=46244669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/078767 WO2012081570A1 (fr) 2010-12-14 2011-12-13 Composé de lactame ou d'un sel de ce dernier, et activateur de ppar

Country Status (2)

Country Link
JP (1) JPWO2012081570A1 (fr)
WO (1) WO2012081570A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153410A1 (fr) * 2014-03-31 2015-10-08 The Trustees Of Columbia University In The City Of New York Activateurs d'histone acétyltransférase et utilisation desdits activateurs
CN106977478A (zh) * 2017-04-21 2017-07-25 山东大学 一种2‑（6‑羟基‑2,3‑二氢苯并呋喃‑3‑基）乙酸甲酯的手性拆分方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480047B (zh) * 2020-12-01 2023-06-02 云南省第二人民医院 一种具有降糖调脂作用的化合物及其制剂与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056522A2 (fr) * 2003-12-04 2005-06-23 National Health Research Institutes Composes indoles
JP2006516254A (ja) * 2003-01-06 2006-06-29 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体
JP2006524220A (ja) * 2003-04-17 2006-10-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｐａｒ活性を変調する化合物及び製造法
WO2009072581A1 (fr) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. Composé lactame ou sel de celui-ci, et activateur du ppar

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516254A (ja) * 2003-01-06 2006-06-29 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体
JP2006524220A (ja) * 2003-04-17 2006-10-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｐａｒ活性を変調する化合物及び製造法
WO2005056522A2 (fr) * 2003-12-04 2005-06-23 National Health Research Institutes Composes indoles
WO2009072581A1 (fr) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. Composé lactame ou sel de celui-ci, et activateur du ppar

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 5, 2007, pages 984 - 1000 *
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, vol. 42, no. 5, 2006, pages 689 - 695 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153410A1 (fr) * 2014-03-31 2015-10-08 The Trustees Of Columbia University In The City Of New York Activateurs d'histone acétyltransférase et utilisation desdits activateurs
US11191768B2 (en) 2014-03-31 2021-12-07 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
CN106977478A (zh) * 2017-04-21 2017-07-25 山东大学 一种2‑（6‑羟基‑2,3‑二氢苯并呋喃‑3‑基）乙酸甲酯的手性拆分方法
CN106977478B (zh) * 2017-04-21 2019-04-09 山东大学 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙酸甲酯的手性拆分方法

Also Published As

Publication number Publication date
JPWO2012081570A1 (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
JP5290749B2 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
KR100202463B1 (ko) 아미노코우마란 유도체, 그들의 제조방법 및 용도
KR101396606B1 (ko) 신규 갑상선 호르몬 β 수용체 작동약
EP3154954B1 (fr) Modulateurs allostériques négatifs (nam) du récepteur métabotropique du glutamate et utilisations de ceux-ci
US7432392B2 (en) Ester derivatives and medical use thereof
JPH10504836A (ja) オルト置換芳香族エーテル化合物及び鎮痛のための薬剤組成物中へのこれらの使用
WO2007085136A1 (fr) Dérivés de 1,3-benzodioxolecyclopentène, procédé de préparation et applications médicales
CA2646430A1 (fr) Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques
WO2003072532A1 (fr) Compose d'esters et ses utilisation en medecine
WO2007085135A1 (fr) Dérivés d'acide 1,3-benzodioxolecyclopentène-2,2-dicarboxylique, procédé de préparation et applications médicales
JP2010533645A (ja) 脂肪酸アミドヒドロラーゼの三環系阻害剤
JP2010533645A5 (fr)
WO2016108282A1 (fr) Inhibiteur d'urat1
AU2014241390A1 (en) GPR120 agonists for the treatment of type II diabetes
JP5892550B2 (ja) 縮合イミダゾール誘導体
JP4191269B2 (ja) 新規なアニリド化合物及びこれを含有する医薬
WO2012081570A1 (fr) Composé de lactame ou d'un sel de ce dernier, et activateur de ppar
KR100677013B1 (ko) 헤테로시클릭 옥심 화합물, 이의 제조 방법 및 이를함유하는 약제학적 조성물
US8524745B2 (en) Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators
CN107922375A (zh) 靶向idh2突变的抗肿瘤化合物及其使用方法
JP6303031B2 (ja) Ｉｉ型糖尿病を処置するためのｇｐｒ１２０アゴニストとしてのイソチアゾール誘導体
JPWO2006126714A1 (ja) ペルオキシソーム増殖剤活性化受容体の活性化剤
JP2018039733A (ja) 新規複素環誘導体
JP2007516986A (ja) 酸性キノリン誘導体ならびに高血糖に関連する病状の予防および／または治療のためのその使用
JP5436941B2 (ja) ラクタム化合物又はその塩及びｐｐａｒ活性化剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11849286

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2012548787

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11849286

Country of ref document: EP

Kind code of ref document: A1